Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Assets (2016 - 2025)

CytomX Therapeutics' Assets history spans 12 years, with the latest figure at $151.6 million for Q4 2025.

  • For Q4 2025, Assets rose 25.75% year-over-year to $151.6 million; the TTM value through Dec 2025 reached $151.6 million, up 25.75%, while the annual FY2025 figure was $151.6 million, 25.75% up from the prior year.
  • Assets reached $151.6 million in Q4 2025 per CTMX's latest filing, down from $158.3 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $434.2 million in Q1 2021 to a low of $98.5 million in Q1 2025.
  • Average Assets over 5 years is $232.3 million, with a median of $215.2 million recorded in 2023.
  • The largest YoY upside for Assets was 25.75% in 2025 against a maximum downside of 46.67% in 2025.
  • A 5-year view of Assets shows it stood at $339.4 million in 2021, then dropped by 23.13% to $260.9 million in 2022, then fell by 22.65% to $201.8 million in 2023, then plummeted by 40.27% to $120.5 million in 2024, then grew by 25.75% to $151.6 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Assets are $151.6 million (Q4 2025), $158.3 million (Q3 2025), and $175.1 million (Q2 2025).